References
- Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G, Schwarz TF, Catteau G, Lal H, Heineman TC. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34(6):863–15. doi:10.1016/j.vaccine.2015.09.073.
- Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833.
- Harpaz R, O-S IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom Rep. 2008;57:1–30. quiz CE32–34.
- Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2):192. doi:10.3390/v14020192.
- Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731–6. doi:10.1503/cmaj.091711.
- Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8(1):37. doi:10.1186/1741-7015-8-37.
- Hadley GR, Gayle JA, Ripoll J, Jones MR, Argoff CE, Kaye RJ, Kaye AD. Post-herpetic neuralgia: a review. Curr Pain Headache Rep. 2016;20(3):17. doi:10.1007/s11916-016-0548-x.
- Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW. et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–26. doi:10.1086/510206.
- Volpi A. Severe complications of herpes zoster. Herpes. 2007;14:35–9.
- Wu PH, Chuang YS, Lin YT. Does herpes zoster increase the risk of stroke and myocardial infarction? A comprehensive review. J Clin Med. 2019;8(4):547. doi:10.3390/jcm8040547.
- Weinke T, Glogger A, Bertrand I, Lukas K. The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany. Sci World J. 2014;2014:749698. doi:10.1155/2014/749698.
- van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021;17(6):1714–32. doi:10.1080/21645515.2020.1847582.
- Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med. 2007;23(3):615–632, vii–viii. doi:10.1016/j.cger.2007.03.003.
- Chan XV, Tan NC, Ng MCW, Ng DX, Koh YLE, Aau WK, Ng CJ. Prevalence and healthcare utilization in managing herpes zoster in primary care: a retrospective study in an Asian urban population. Front Public Health. 2023;11:1213736. doi:10.3389/fpubh.2023.1213736.
- Department of Statistics Singapore, SingStat. Population and population structure; 2022 [accessed 2023 Apr]. https://tablebuilder.singstat.gov.sg/statistical-tables/downloadMultiple/zX5lZdqFrk-29wjZN4FFXw.
- Fatha N, Ang LW, Goh KT. Changing seroprevalence of varicella zoster virus infection in a tropical city state, Singapore. Int J Infect Dis. 2014;22:73–7. doi:10.1016/j.ijid.2013.10.003.
- Chen Q, Hsu T-Y, Chan R, Kawai K, Acosta CJ, Walia A, Pan JY. Clinical and economic burden of herpes zoster and postherpetic neuralgia in patients from the National Skin Centre, Singapore. Dermatol Sin. 2015;33(4):201–5. doi:10.1016/j.dsi.2015.04.002.
- Werner RN, Nikkels AF, Marinovic B, Schafer M, Czarnecka-Operacz M, Agius AM, Bata-Csorgo Z, Breuer J, Girolomoni G, Gross GE. et al. European consensus-based (S2k) guideline on the management of herpes zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: treatment. J Eur Acad Dermatol Venereol. 2017;31(1):20–9. doi:10.1111/jdv.13957.
- Qi T, Lan H, Zhong C, Zhang R, Zhang H, Zhu F, Ji B. Systematic review and meta-analysis: the effectiveness and safety of acupuncture in the treatment of herpes zoster. Ann Palliat Med. 2022;11(2):756–65. doi:10.21037/apm-22-109.
- Gan EY, Tian EA, Tey HL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol. 2013;14(2):77–85. doi:10.1007/s40257-013-0011-2.
- Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis. 2007;11(Suppl 2):S43–48. doi:10.1016/S1201-9712(07)60021-6.
- Miyachi M, Imafuku S. Relationship between prior knowledge about herpes zoster and the period from onset of the eruption to consultation in patients with herpes zoster. J Dermatol. 2016;43(10):1184–7. doi:10.1111/1346-8138.13334.
- Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014(2):CD006866. doi:10.1002/14651858.CD006866.pub3.
- Katz J, Cooper E, Walther R, Sweeney E, Dworkin R. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39(3):342–8. doi:10.1086/421942.
- Dworkin R, Schmader K. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003;36(7):877–82. doi:10.1086/368196.
- Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6(6):356–63. doi:10.1016/j.jpain.2005.01.359.
- Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh SS, Levin MJ, Harbecke RM. et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58(9):1634–41. doi:10.1111/j.1532-5415.2010.03021.x.
- Curran D, Matthews S, Rowley SD, Young JH, Bastidas A, Anagnostopoulos A, Barista I, Chandrasekar PH, Dickinson M, El Idrissi M. et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019;25(12):2474–81. doi:10.1016/j.bbmt.2019.07.036.
- Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E. et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. 2019;74(8):1231–8. doi:10.1093/gerona/gly150.
- Ministry of Health, Singapore. White paper on Healthier SG; 2022 [accessed 2023 May]. https://file.go.gov.sg/healthiersg-whitepaper-pdf.pdf.
- Shingrix [package insert]. Singapore: GSK group of companies; 2022.
- Zostavax [package insert]. Singapore: MSD; 2022.
- Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. doi:10.1056/NEJMoa1501184.
- Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J. et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. doi:10.1056/NEJMoa1603800.
- Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84. doi:10.1056/NEJMoa051016.
- Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al. Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis. 2012;55(10):1320–8. doi:10.1093/cid/cis638.
- Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R. et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–9. doi:10.1093/cid/ciu918.
- Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103–8. doi:10.15585/mmwr.mm6703a5.
- Health Sciences Authority, Singapore. PZ4970 Infosearch - therapeutic products; 2021 [accessed 2023 May]. https://eservice.hsa.gov.sg/prism/common/enquirepublic/SearchDRBProduct.do?action=load&_ga=2.183810082.563179921.1554083187-551332391.1551944793.
- Society of Infectious Disease, Singapore. Handbook on adult vaccination in Singapore 2023; 2023 [accessed 2024 May]. https://www.cfps.org.sg/assets/Circulars/2023/SG-SID-001-Handbook-v15-Highres-bleed.pdf.
- Ministry of Health, Singapore. Nationally recommended vaccines; 2021 [accessed 2023 Apr]. https://www.moh.gov.sg/resources-statistics/nationally-recommended-vaccines.
- Patterson BJ, Buck PO, Curran D, Van Oorschot D, Carrico J, Herring WL, Zhang Y, Stoddard JJ. Estimated public health impact of the recombinant zoster vaccine. Mayo Clin Proc Innov Qual Outcomes. 2021;5(3):596–604. doi:10.1016/j.mayocpiqo.2021.03.006.
- McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, Varghese L, Curran D. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17(5):723–32. doi:10.1007/s40258-019-00491-6.
- Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213–21. doi:10.1080/21645515.2017.1345399.
- Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother. 2021;17(12):5296–303. doi:10.1080/21645515.2021.2002085.
- Watanabe D, Mizukami A, Holl K, Curran D, Van Oorschot D, Varghese L, Shiragami M. The potential public health impact of herpes zoster vaccination of people aged ≥ 50 years in Japan: results of a Markov model analysis. Dermatol Ther (Heidelb). 2018;8(2):269–84. doi:10.1007/s13555-018-0236-3.
- Chan PKS, Wong MCS, Chan M, Ching K, Giannelos N, Ng C. Public health impact of herpes zoster vaccination on older adults in Hong Kong. Hum Vaccin Immunother. 2023;19(1):2176065. doi:10.1080/21645515.2023.2176065.
- Lee C, Jiang N, Tang H, Ye C, Yuan Y, Curran D. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. Hum Vaccin Immunother. 2021;17(10):3735–46. doi:10.1080/21645515.2021.1932216.
- Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, Chang LY. Varicella-Zoster Working Group, Advisory Committee on Immunization Practices Taiwan. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28(5):1217–20. doi:10.1016/j.vaccine.2009.11.029.
- Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, Chen CC, Lee DD, Chang YT, Wang WJ. et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009;89(6):612–6. doi:10.2340/00015555-0729.
- Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol. 1997;36(9):667–72. doi:10.1046/j.1365-4362.1997.00241.x.
- Yawn B, Saddier P, Wollan PC, St. Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clinic Proc. 2007;82(11):1341–9. doi:10.4065/82.11.1341.
- Lu WH, Lin CW, Wang CY, Chen LK, Hsiao FY. Epidemiology and long-term disease burden of herpes zoster and postherpetic neuralgia in Taiwan: a population-based, propensity score-matched cohort study. BMC Public Health. 2018;18(1):369. doi:10.1186/s12889-018-5247-6.
- Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7):489–97. doi:10.7326/M15-0093.
- HealthyPeople.gov, U.S. Department of Health and Human Services. Immunization and infectious diseases data details; 2020 [accessed 2023 Apr]. https://wayback.archive-it.org/5774/20210211114047/https://www.healthypeople.gov/node/3527/data-details.
- Wick JY. Pharmacy Times. HP2020 herpes zoster immunization goal has been met; 2020 [accessed 2023 Apr]. https://www.pharmacytimes.com/view/hp2020-herpes-zoster-immunization-goal-has-been-met.
- LaMori J, Feng X, Pericone CD, Mesa-Frias M, Sogbetun O, Kulczycki A. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017–2021. Vaccine. 2022;40(15):2266–73. doi:10.1016/j.vaccine.2022.03.006.
- Ministry of Health, Singapore. Merdeka generation package; 2023 [accessed 2023 Sep]. https://www.moh.gov.sg/healthcare-schemes-subsidies/merdeka-generation-package.
- Ministry of Health, Singapore. Pioneer generation package; 2023 [accessed 2023 Sep]. https://www.moh.gov.sg/healthcare-schemes-subsidies/pioneer-generation-package.
- Chen LK, Arai H, Chen LY, Chou MY, Djauzi S, Dong B, Kojima T, Kwon KT, Leong HN, Leung EM. et al. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. BMC Infect Dis. 2017;17(1):213. doi:10.1186/s12879-017-2198-y.
- Curran D, Callegaro A, Fahrbach K, Neupane B, Vroling H, van Oorschot D, Yawn BP. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11(1):389–403. doi:10.1007/s40121-021-00567-8.
- Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011;86(2):88–93. doi:10.4065/mcp.2010.0618.
- Kim YJ, Lee CN, Lee MS, Lee JH, Lee JY, Han K, Park YM. Recurrence rate of herpes zoster and its risk factors: a population-based cohort study. J Korean Med Sci. 2019;34(2):e1. doi:10.3346/jkms.2019.34.e1.
- You JHS, Ming WK, Tsang OT, Chan PK. Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. PLOS ONE. 2019;14(1):e0210005. doi:10.1371/journal.pone.0210005.
- Mahamud A, Marin M, Nickell SP, Shoemaker T, Zhang JX, Bialek SR. Herpes zoster-related deaths in the United States: validity of death certificates and mortality rates, 1979–2007. Clin Infect Dis. 2012;55(7):960–6. doi:10.1093/cid/cis575.
- Pan CX, Lee MS, Nambudiri VE. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. Ther Adv Vaccines Immunother. 2022;10:25151355221084535. doi:10.1177/25151355221084535.
- Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ. et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74(8):1459–67. doi:10.1093/cid/ciab629.
- European Medicines Agency. Shingrix: EPAR – Product information; 2022 [accessed 2023 Sep]. https://www.ema.europa.eu/en/documents/product-information/shingrix-epar-product-information_en.pdf.
- Kim JH, Diaz-Decaro J, Jiang N, Hwang SJ, Choo EJ, Co M, Hastie A, Hui DSC, Irimajiri J, Lee J. et al. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Hum Vaccin Immunother. 2021;17(7):2050–7. doi:10.1080/21645515.2020.1859321.
- SingHealth. Shingles (herpes zoster) vaccine; 2021 [accessed 2023 May]. https://www.singhealth.com.sg/patient-care/medicine/shingles-herpes-zoster-vaccine/.
- Pan J, Hsu T-Y, Johnson KD, Xu R, Acosta CJ, Kawai K. Cost-effectiveness analysis of herpes zoster vaccine in adults above 50 in Singapore. Dermatol Sin. 2017;35(4):177–81. doi:10.1016/j.dsi.2017.04.011.
- Pharmaceuticals Benefits Advisory Committee. Public summary document – March 2023 PBAC meeting; 2023 [accessed 2023 Jul]. https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2023-03/files/varicella-zoster-vaccine-psd-03-2023.pdf.
- The Standing Committee on Vaccination, Robert Koch Institute. Immunisation schedule; 2023 [accessed 2023 May]. https://www.rki.de/DE/Content/Infekt/Impfen/Materialien/Downloads-Impfkalender/Impfkalender_Englisch.pdf?__blob=publicationFile.
- Siedler A, Koch J, Garbe E, Hengel H, von Kries R, Ledig T, Mertens T, Zepp F, Uberla K. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine: statement of the German Standing Committee on vaccination (STIKO) at the Robert Koch Institute. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62(3):352–76. doi:10.1007/s00103-019-02882-5.
- GOV.UK, UK Health Security Agency. Introduction of Shingrix® vaccine for the whole programme and expansion of eligible cohorts letter; 2023 [accessed 2023 Jul]. https://www.gov.uk/government/publications/shingles-vaccination-programme-changes-from-september-2023-letter/introduction-of-shingrix-vaccine-for-the-whole-programme-and-expansion-of-eligible-cohorts-letter.
- Ministry of Health – Manatū Hauora, New Zealand. New Zealand immunisation schedule; 2023 [accessed 2023 May]. https://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/new-zealand-immunisation-schedule.
- Pharmac Te Pātaka Whaioranga, New Zealand. Proposal to widen access to the meningococcal B vaccine and secure supply of the shingles vaccine; 2022 [accessed 2023 May]. https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-10-25-proposal-to-widen-access-to-the-meningococcal-b-vaccine-and-secure-supply-of-the-shingles-vaccine/?keyword=shingrix&type=all&page=1.
- Ministry of Manpower, Singapore. Retirement; 2022 [accessed 2023 Jul]. https://www.mom.gov.sg/employment-practices/retirement.
- Ministry of Manpower, Singapore. Strengthening support for senior workers; 2021 [accessed 2023 Jul]. https://www.mom.gov.sg/-/media/mom/documents/press-releases/2021/1101-rraa—twg-ow-infographic.pdf.
- Ministry of Manpower, Singapore. Resident labour force by age and sex; 2023 [accessed 2023 May]. https://stats.mom.gov.sg/iMAS_Tables1/Time-Series-Table/mrsd_20_Res_labour_force_by_age_sex.xlsx.
- National Population and Talent Division, Strategy Group, Prime Minister’s Office, Singapore. Population in brief 2022; 2022 [accessed 2023 Sep]. https://www.strategygroup.gov.sg/files/media-centre/publications/population-in-brief-2022.pdf.
- HealthHub, Health Promotion Board, Singapore. Stay one step ahead with vaccinations; 2023 [accessed 2023 May]. https://www.healthhub.sg/programmes/163/vaccinate.
- Wang JH, Adams IF, Pasick RJ, Gomez SL, Allen L, Ma GX, Lee MX, Huang E. Perceptions, expectations, and attitudes about communication with physicians among Chinese American and non-Hispanic white women with early stage breast cancer. Support Care Cancer. 2013;21(12):3315–25. doi:10.1007/s00520-013-1902-8.
- Xia Y, Zhang X, Zhang L, Fu C. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: a systematic review and network meta-analysis. Front Immunol. 2022;13:978203. doi:10.3389/fimmu.2022.978203.
- Sansone RA, Sansone LA. Herpes zoster and postherpetic neuralgia: an examination of psychological antecedents. Innov Clin Neurosci. 2014;11:31–4.
- Chen HH, Lin IC, Chen HJ, Yeh SY, Kao CH. Association of herpes zoster and type 1 diabetes mellitus. PLOS ONE. 2016;11(5):e0155175. doi:10.1371/journal.pone.0155175.
- Tung YC, Tu HP, Wu MK, Kuo KL, Su YF, Lu YY, Lin CL, Wu CH. Higher risk of herpes zoster in stroke patients. PLOS ONE. 2020;15(2):e0228409. doi:10.1371/journal.pone.0228409.
- Ke CC, Lai HC, Lin CH, Hung CJ, Chen DY, Sheu WH, Lui PW. Increased risk of herpes zoster in diabetic patients comorbid with coronary artery disease and microvascular disorders: a population-based study in Taiwan. PLOS ONE. 2016;11(1):e0146750. doi:10.1371/journal.pone.0146750.
- Orhan VA, Avarisli A. Advanced age and multiple comorbidities as important factors in predicting poor prognosis in herpes zoster ophthalmicus. Cureus. 2021;13(9):e18412. doi:10.7759/cureus.18412.
- Li Z, Wang Q, Ma J, Li Z, Huang D, Huang Y, Zhou H. Risk factors for herpes zoster in patients with chronic kidney disease: a case-control study. Vaccines. 2021;9(9):963. doi:10.3390/vaccines9090963.
- Imafuku S, Dormal G, Goto Y, Jegou C, Rosillon D, Matsuki T. Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: results from a claims database cohort study, from 2005 to 2014. J Dermatol. 2020;47(3):236–44. doi:10.1111/1346-8138.15214.
- Low LL, Kwan YH, Ko MSM, Yeam CT, Lee VSY, Tan WB, Thumboo J. Epidemiologic characteristics of multimorbidity and sociodemographic factors associated with multimorbidity in a rapidly aging Asian country. JAMA Netw Open. 2019;2(11):e1915245. doi:10.1001/jamanetworkopen.2019.15245.
- Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005. doi:10.1093/ofid/ofaa005.
- Huang CT, Lee CY, Sung HY, Liu SJ, Liang PC, Tsai MC. Association between diabetes mellitus and the risk of herpes zoster: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2022;107(2):586–97. doi:10.1210/clinem/dgab675.
- Bee YM, Tai ES, Wong TY. Singapore’s “war on diabetes”. Lancet Diabetes Endocrinol. 2022;10(6):391–2. doi:10.1016/S2213-8587(22)00133-4.